Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-09-20
2005-09-20
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S263100, C514S266400, C536S027300, C536S027630, C544S264000
Reexamination Certificate
active
06946449
ABSTRACT:
Disclosed are novel compounds that are partial and full A1adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.
REFERENCES:
patent: 6258793 (2001-07-01), Palle et al.
patent: 0181129 (1986-05-01), None
patent: 116 401 (2001-01-01), None
patent: WO 99/24449 (1999-05-01), None
patent: WO 99/24450 (1999-05-01), None
patent: WO 99/24451 (1999-05-01), None
patent: WO 99/67262 (1999-12-01), None
patent: WO 99/67262 (1999-12-01), None
patent: WO 01/40243 (2001-06-01), None
Tilburg et al, J. Med. Chem., vol. 42, pp. 1393-1400.
Brackett L E et al: “Functional Characterization of the A2B Adenosine Receptor in NIH 3T3 Fibroblasts”, Biochemical Pharmacology, Pergamon, Oxford, GB, vol. 47, No. 5, 1994, pp. 801-814 XP000942545, ISSN: 0006-2952 abstract.
Marumoto R et al: “Synthesis and Enzymatic Activity of Adenosine 3′ , 5′-Cyclic Phosphate Analogs”, Chemical and Pharmaceutical Bulletin, Pharmaceutical Society of Japan. Tokyo, JP., vol. 27, No. 4, 1979, pp. 990-1003, ISSN: 0009-2363, “chart 3”, p. 992, table 3.
Munro R et al, “Differential expression of adenosine A2A and A2B receptor subtypes of myeloid U937 and THP-1 cells: Adenosine A2B receptor activation selectively stimulates cAMP formation and inhibition of TNFalpha release in THP-1 cells,” Drug Development Research, vol. 44, No. 1, May 1998, pp. 41-47 ISSN: 0272-4391.
Van Der Wenden, E. et al: “5′-Substituted adenosine analogs as new high-affinity partial agonists for the adenosine A1 receptor”, J. Med Chem, 1998, 41, pp. 102-108.
Tilburg, E. et al: “N6.5′-Disubstituted adenosine derivatives as partial agonists for the human adenosine A3 receptor”, J. Med. Chem, 1999, 42, pp. 1393-1400.
R.M. Smejkal et al. (1989) “Muscarinic receptor subtype specificity of 5′(isobutylthio)-adenosine (SIBA) and its analogues,” Gen. Pharmac., 20(3):385-392, XP008022164.
Elzein Elfatih
Ibrahim Prabha
Palle Venkata
Varkhedkar Vaibhav
Zablocki Jeff
Clarke Pauline Ann
CV Therapeutics Inc.
Hartrum J. Elin
Lewis Brian
Owens, Jr. Howard V.
LandOfFree
Partial and full agonists of A1 adenosine receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Partial and full agonists of A1 adenosine receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Partial and full agonists of A1 adenosine receptors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3397203